Martigny, Switzerland

Olivier Turpin

This inventor holds 1 USPTO granted patent. Top assignee: Debio Recherche Pharmaceutique S.a.. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olivier Turpin. Retrieved from https://idiyas.com/inventor/olivier-turpin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Olivier Turpin: Innovator in Medicinal Chemistry

Introduction

Olivier Turpin is a notable inventor based in Martigny, Switzerland. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antiviral agents.

Latest Patents

Olivier Turpin holds a patent for "Cycloundecadepsipeptide compounds and use of said compounds as a medicament." This invention focuses on new cycloundecadepsipeptide compounds and their application as antiviral agents, specifically for preventing or treating Hepatitis C infections and HCV-induced disorders.

Career Highlights

Turpin is associated with Debio Recherche Pharmaceutique S.A., where he has been instrumental in advancing research in pharmaceutical sciences. His work has contributed to the development of innovative treatments that address critical health issues.

Collaborations

Olivier has collaborated with esteemed colleagues, including Roland M Wenger and Manfred Mutter, to further enhance the impact of his research and inventions.

Conclusion

Olivier Turpin's work exemplifies the importance of innovation in the pharmaceutical industry, particularly in the fight against viral infections. His contributions continue to pave the way for new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…